Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifestyle Intervention Plus Metformin for Frailty in Obese Older Veterans
NCT04221750Phase 3Completed
- Sponsor
- VA Office of Research & Development
- Start
- May 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of liquid metformin (Aspargo Labs) in frailty syndrome and Sarcopenic Obesity (SO) (3 arms), sponsored by VA Office of Research & Development. Primary endpoint: Modified Physical Performance Test at 6 months. Started May 2021; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
frailty syndromeSarcopenic Obesity (SO)
Beyond the preview
Go deeper on NCT04221750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221750.